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Vaccine Children (n ¼ 18) Adults (n ¼ 45)
Tetanus 77% 63%
Diphtheria 79% 74%
Pertussis 92% 61%
Haemophilus inﬂ. B 88% 91%
Polio 85% 76%
Pneumococcus 60% 46%
Table 1
Timing of PCP infection after HSCT and differences among cases vs. controls
Factor <60 days 60-270 days >270 days
Proportion of PCP cases 26% 51% 24%
Bactrim prophylaxis* 36% vs. 35% 14% vs. 43% 11% vs. 21%
Grade 3-4 aGVHD* 29% vs. 17% 31% vs. 24% 42% vs. 21%
cGVHD* 79% vs. 44%
*Cases vs. controls; performed on nested case control analysis from data
collected on secondary forms of allo HSCT (n¼ 117).
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transplanted for hematologic malignancies with CNI/MMF
prophylaxis between 10/2005-2/2012. Vaccination criteria
were 1 year post-CBT (earlier in select children), CD4+
>200 cells/ul, & independence from IVIg.
Results: Of 132 patients transplanted, 41 died or relapsed
prior to 1-year. Of 91 remaining patients, 67 (74%) were
vaccinated of whom 63 were evaluable with titer responses.
GVHD was the most common reason for survivors not to be
vaccinated (18/91, 20%). Median age of 63 evaluable vaccine
recipients was 34 years (range 0.9-64); the median time to
vaccination was +17 months (range 7-45). Vaccination was
delayed in 39 CBTs with prior gr. II-IV acute &/or mod-severe
chronic GVHD (+17 months, range 9-45) compared to no
signiﬁcant prior GVHD (+14 months, range 7-33), & in 13
Rituximab (+19 months, range 12-45) recipients. Responses
to the primary series vaccines in children < 18 years & adults
are shown (Table). Responses were seen even in the setting
of prior GVHD or prior Rituximab. Immune function prior to
vaccination did not inﬂuence responses to pneumococcus, H.
inﬂuenza, pertussis or diphtheria vaccines. However, those
with recovery > median CD4+CD45RA+ (>127/ul) & CD19+
(> 793/ul) counts had increased likelihood of tetanus (p ¼
.09 & p ¼ .04) & polio (p ¼ .05 & p ¼ .02) responses. There
were no serious vaccine reactions & with a median 54 month
(range 22-96) follow-up of vaccinated patients, their survival
is 100%.
Conclusions: CBT recipients, including adults & those with
prior GVHD, are capable of responding to tetanus, diphtheria,
pertussis, H. Inﬂuenza, polio & pneumococcal conjugate
vaccines similar to reported adult donor allograft series.
Furthermore, our data suggests improved immune recovery
(CD4+45RA+ & CD19+ subsets) prior to vaccination can
augment vaccine efﬁcacy. However, GVHD can hinder the
ability to commence vaccines in long-term survivors. Addi-
tionally, the sub-optimal responses to non-live vaccines in
some recipients highlight the need to obtain pre- & post-
vaccine titers to document responses, investigate the optimal
timing & number of vaccines, & the role of boosters & CD27+
memory B-cell measurement to predict response.
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Pneumocystis jiroveci pneumonia (formerly PCP) is associ-
ated with high morbidity and mortality after HSCT. Little is
known about PCP infections after HSCT due to presumed
rarity of disease after the advent of prophylaxis. We report
results of a CIBMTR study evaluating the incidence, timing,
prophylaxis agents, risk factors, and mortality of PCP in
autologous (auto) and allogeneic (allo) HSCT recipients. For
recipients of ﬁrst HSCT captured between 1995 and 2005,
PCP infection was documented in 0.63% (n¼177) of allo
(n¼27,934) and 0.28% (n¼52) of auto (n¼18525) HSCT. After
allo-HSCT, cases were distributed early and late after HSCT
(Table 1). A nested case control study was performed con-
trolling for auto vs. allo, primary disease, and alive at PCP
diagnosis, to evaluate risk factors for PCP, the inﬂuence of
PCP prophylaxis agents on the risk of PCP, and the effect of
PCP on overall survival using supplemental data (n¼68 allo
cases, n¼111 allo controls). In univariate analysis, PCP
infection was higher among recipients who were not
Caucasian (p¼.001), received PB (vs. BM) (p¼.027), campath/
ATG (p ¼ .02), less well-matched grafts (p ¼ <.001), and had
lymphopenia (p<.001) or steroids (p <.001) in the 30 days
prior to PCP. Other risk factors are described by onset time of
PCP after HSCT (Table 1). Prophylaxis agents varied but the
use of Bactrim was lower in cases occurring late. There were
more cases with grade 3-4 acute GVHD and chronic GVHD vs.
controls. After allo HSCT, overall survival (OS) was signiﬁ-
cantly poorer among cases vs. controls [1 year: 41% vs. 73%
(p<.0001); 5 year: 25% vs. 56% (p<.0001)]. Similarly,
following auto HSCT, OS was lower in cases vs. controls
(1year: 42% vs. 86% (p¼.0004); 5 year: 13% vs. 52%
(p¼.0003)). After controlling for signiﬁcant variables (age,
disease status, GVHD prophylaxis, year of HSCT, aGVHD),
proportional hazards model revealed that PCP cases were
6.87x more likely to die vs. matched controls (p<.0001, CI
4.84-9.75). Thus, these data reveal that: PCP infection is rare
after HSCT; PCP occurs both early and late after HSCT;
mismatch, GVHD prophylaxis, and GVHD and steroids are
risk factors for PCP; and PCP infection is associated with
higher mortality rate after allo and auto HSCT. Furthermore,
our data suggest opportunities to improve supportive care,
starting PCP prophylaxis early post-HSCT and continuing for
those with these newly identiﬁed risk factors: GVHD, steroid
exposure, or poor immune reconstitution.CRA -DATA MANAGEMENT109
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Background: To ensure the highest degree of accuracy for
the CIBMTR (Center for International Blood and Marrow
Transplant Research) data, the Penn State Milton S. Hershey
Medical Center Bone Marrow Transplant Program has
created Powerforms integrated into the EMR (Electronic
Medical Record) for GVHD (Graft versus Host Disease) and PS
(Performance Status) Assessment. In 2008, the data manager
was able to change the GVHD and PS Assessment from a
paper based method to an Electronic method.
Methods: The Bone Marrow Transplant Data Manager col-
lects GVHDAssessment for all Allogeneic Transplant patients,
and Assessments for patients on the research track at the
time periods of Day 100, six months, and yearly post-trans-
plant. The assessments are collected in the EMR. The
Attending Physicians then review, modify if needed, and sign
the assessment forms. These forms are used as source
documentation during CIBMTR Data Submission Audits.
Results: Our results show a decrease in errors found during a
CIBMT audit. The NMDP Audit in 2004 showed an overall
error rate (OER) of 1.2% and a Critical Error Rate (CER) of 2.8%.
PS errors were 47.9% of the CER, and GVHD errors were 14.6%
of the CER. In 2008, the audit showed a 1.7% OER and a 3.8%
CER. PS errors were 24.5% of the CER, and GVHDwere 3.8% of
the CER. In 2012, the audit showed a 0.7% OER and a 0.8% CER.
PS errors were 4.3% of CER and GVHD were 4.3% of CER.
Conclusion: Implementing the collection of GVHD and PS
assessment using the EMR has decreased the error rate found
on the CIBMTR Audit. The continuation of this method of
data collection can further reduce the error rate.
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Accurate patient data reporting is essential for the validity of
the scientiﬁc conclusions based on the international data-
bases (DB) of CIBMTR and EBMT. A study request from EMBT
listing patients with CML, raised suspicion that the list was
incomplete and that data had not been correctly reported. To
identify if data were missing and if so whether the problem
was, a) internal (local DB, data entering etc.), b) external
(EBMT/CIBMTR DB), c) random, or d) systematic, a quality
control survey was initiated.
Aim: To ensure all CML patients were reported correctly and
to identify the cause of possible errors.
Methods: Before the 1st of July 2013 the previous 20 patients
with CML treated with allogeneic stem cell transplantation
(SCT) were audited for data accuracy (Nov 5th 2007 - July
1st2013). The following data were checked for accuracy:
diagnosis, date of diagnoses, molecular markers, cytogenetic,
pre transplant treatment, and use of thyrosine kinase in-
hibitors (TKI). The data accuracy was checked in the EBMT,
the CIBMTR and the local DB. Data entering have been per-
formed by the EBMT, the CIBMTR and online by the data
managers at our institution.
Results: For the 20 CML patients, the diagnoses, the date of
diagnosis and cytogenetics were reported correctly in all
DBs. In relation to all other data, no error was identiﬁed in
the CIBMTR DB. However, two of 20 patients had a coding
error in relation to molecular markers in the EBMT DB, but
not in the local DB. In relation to treatment, two patients had
a coding error in the EBMT DB and one patient in the localDB. In relation to the ﬁrst course of TKI treatment three pa-
tients had a coding error in the EBMT DB and one in the local
DB. In relation to the second course of TKI eight patients had
a coding error in the local DB and two in the EBMT DB.
Conclusion: All data were entered correctly in the CIBMTR
DB, however errors were identiﬁed in the EBMTand the local
DB. Accordingly, the cause of errors is not related to lack of
knowledge of CML biology. The identiﬁed errors were not
systematically since they did not related to all patients.
Therefore it can be assumed that the errors were random
data entering errors. When analyzing the data entering
process in the three different data bases, the CIBMTR form
and DB are identical. However, the MED A form is not iden-
tically to the EBMT DB and neither of the forms is identical to
the local DB. Therefore interpretation of data during the data
entering process may be a source for coding errors. In the
future regular audit of data are recommended.111
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Background: Efﬁciency of delivery and coordination of pa-
tient care continues to be a challenge for most transplant
programs. Growth in transplant volumes at centers continues
to outpace growth in medical provider workforce. TIPS is a
transplant patient workﬂow management database centered
on streamlining workﬂow practices within a Blood and
Marrow Transplant (BMT) Program. The database associates
medical providers with speciﬁc roles that govern the various
stages of patient care. As each role completes speciﬁc trans-
plant tasks, TIPS transitions the patient to the subsequent
stage of the transplant. These stages include intake, pre-
transplant, admit/prep-regimen, post-transplant, discharge/
follow-up. TIPS Dashboard provides BMT Program adminis-
trators with real-time graphical representation of their
transplant patient population categorized by stage, disease,
staff workload etc. TIPS Reporting interface provides ease of
RFI reporting and data extraction. TIPS functionality includes
single click automated admission/discharge letters, insurance
authorizations request letters, transplant schedule report, and
comorbidity calculation. We have transitioned our in-house
Transplant Information Patient System (TIPS) to a web-based
collaborative platform to expand accessibility.
Methods: TIPS was originally developed on a Microsoft Ac-
cess database platform. However accessibility was limited
due to client side software availability, and local area
network access. These limitations were eliminated on tran-
sitioning to a web-based platform. The new TIPS web-based
version is developed on the Yii framework utilizing PHP,
JQuery, and CSS, with a MySQL backend database. TIPS
